Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company's licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical's DNA delivery technology. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee (IDMC) recommended stopping the trial early to prevent potential ethical issues against the placebo group subjects. AnGes is ending the trial and preparing to file an application for Japanese marketing approval.

"The successful Phase 3 results from our Japanese licensee position the AnGes product candidate to be the first approved for human use based on our DNA delivery technology and provide proof of concept for DNA delivery in the treatment of disease," said Vijay B. Samant, President and Chief Executive Officer of Vical. "This novel approach has the potential to address an important, unserved medical need in a significant commercial market. We look forward to further updates from AnGes as they advance through the regulatory approval process."

The treatment uses Vical technology to deliver a gene encoding Hepatocyte Growth Factor (HGF), a human protein that causes angiogenesis (growth of blood vessels) in areas of ischemia (restricted blood flow). In the trial, 40 subjects with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The primary endpoints, improvement of rest pain ((VAS (Visual Analog Scale)) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in the placebo group and 70.4% improvement in the treatment group, a statistically significant difference (p=0.014).

The following English
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... its pipeline and new product development efforts. In the ... a Phase 2a study of AZ-002 (Staccato ® ... management of patients with acute repetitive seizures.  Additionally, ... product candidates for development - AZ-008 and AZ-009 ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... held on Friday, June 17, 2011. At the meeting, shareholders ... of incorporation to increase the total number of authorized shares ... About Cell Therapeutics, Inc. Headquartered in ...
... Pharmaceuticals, Inc. is initiating a voluntary recall of ... by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and ... Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of ... consumer reports of an uncharacteristic odor thought to ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 3Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 4Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 5Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 6Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 7
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
(Date:7/31/2014)... July 31, 2014 In many states and ... for proper storage of necessary life saving drugs. This requirement ... there is still a high number of ambulances without proper ... who steals the narcotics and even replaces the vital pain ... none. As seen in the case in Baraboo, Wisconsin last ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... March 29 The second annual,National Walk for ... and raised $1.5 million to help build awareness ... to raise much-needed funds. The event,was sponsored by ... http://www.newscom.com/cgi-bin/prnh/20080329/17897 ), The stars coming ...
... 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... the American College of Cardiology,s 57th Annual Scientific ... Among the most significant presentations are the following: ... Transplant Allograft Vasculopathy , Dr. Jeffrey ...
... room for improvement in balancing seizure control ... and medication-related side ... of the nation,s,largest event dedicated to the epilepsy community, ... in response to a,new national survey uncovering key challenges ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... Ranks above National Average in Overall Patient Satisfaction and Other ... ... The Hospital Quality Alliance today,released the first Hospital Consumer Assessment of ... care as rated by patients themselves. Hospital for Special Surgery,(HSS) in New ...
Cached Medicine News:Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:National Walk for Epilepsy Brings People and Celebrities Together for Epilepsy 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 2Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 4Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 5Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: